Search results for "Serotonin receptor antagonist"

showing 3 items of 3 documents

Spasmolytic Effects of Aphanizomenon Flos Aquae (AFA) Extract on the Human Colon Contractility.

2021

The blue-green algae Aphanizomenon flos aquae (AFA), rich in beneficial nutrients, exerts various beneficial effects, acting in different organs including the gut. Klamin® is an AFA extract particularly rich in β-PEA, a trace-amine considered a neuromodulator in the central nervous system. To date, it is not clear if β-PEA exerts a role in the enteric nervous system. The aims of the present study were to investigate the effects induced by Klamin® on the human distal colon mechanical activity, to analyze the mechanism of action, and to verify a β-PEA involvement. The organ bath technique, RT-PCR, and immunohistochemistry (IHC) were used. Klamin® reduced, in a concentration-dependent manner, …

MaleColonmotility discomfortMethysergideGene ExpressionPharmacologyArticle-PEAContractilityTAAR1medicineSerotonin receptor antagonistAphanizomenonHumansTX341-641Myenteric plexusAgedhuman colon contractilityAged 80 and overBiological ProductsAFA extractNutrition and DieteticsDose-Response Relationship DrugChemistryNutrition. Foods and food supplyParasympatholyticsEPPTBMuscle SmoothKlamin®Middle AgedKlamin<sup>®</sup>ImmunohistochemistryMechanism of actionDietary SupplementsEnteric nervous systemFemalePeristalsismedicine.symptomBiomarkersβ-PEAFood Sciencemedicine.drugMuscle ContractionNutrients
researchProduct

Evaluation of [11C]Metergoline as a PET Radiotracer for 5HTR in Nonhuman Primates

2010

Metergoline, a serotonin receptor antagonist, was labeled with carbon-11 in order to evaluate its pharmacokinetics and distribution in non-human primates using positron emission tomography. [{sup 11}C]Metergoline had moderate brain uptake and exhibited heterogeneous specific binding, which was blocked by pretreatment with metergoline and altanserin throughout the cortex. Non-specific binding and insensitivity to changes in synaptic serotonin limit its potential as a PET radiotracer. However, the characterization of [{sup 11}C]metergoline pharmacokinetics and binding in the brain and peripheral organs using PET improves our understanding of metergoline drug pharmacology.

PrimatesMetergolinemedicine.medical_specialtyBiodistributionClinical BiochemistryPharmaceutical ScienceBiochemistryArticlechemistry.chemical_compoundPharmacokineticsInternal medicineDrug DiscoverymedicineDistribution (pharmacology)Serotonin receptor antagonistAnimalsTissue DistributionCarbon RadioisotopesMolecular BiologyChemistryOrganic ChemistryAntagonistBrainEndocrinologyPositron-Emission TomographyReceptors SerotoninAltanserinMetergolineMolecular MedicineSerotoninRadiopharmaceuticalsProtein Binding
researchProduct

Fluorine-containing drugs approved by the FDA in 2019

2020

Abstract Eleven new fluorine-containing FDA-approved drugs have been profiled and details of their discovery and preparation are discussed. Therapeutic areas include schizophrenia, migraine, multiple sclerosis, insomnia, rheumatoid arthritis, anti-tuberculosis, breast cancer, lymphoma kinase inhibitor, serotonin receptor antagonist. New pharmaceuticals feature four examples of aromatic fluorine, three aromatic CF3 group, three aliphatic CF3 and one compound with aromatic CF3O group. Furthermore, among the new compounds, six are chiral and seven are derived from tailor-made amino acids.

chemistry.chemical_classificationKinasebusiness.industry03.01. Általános orvostudományFluorine containing02 engineering and technologyGeneral ChemistryPharmacology010402 general chemistry021001 nanoscience & nanotechnologymedicine.disease01 natural sciences0104 chemical sciencesAmino acidBreast cancerchemistryMigraineRheumatoid arthritismedicineSerotonin receptor antagonist0210 nano-technologybusinessChinese Chemical Letters
researchProduct